First-In-Class Pharmaceutical Therapies Nasdaq Stock

Top-line data is around the corner and it may fuel big moves for this eye care stock. Unsubscribe A Message from Smallcaps Daily   Top-line data is around the corner and it may fuel big moves for this eye care stock. Eye diseases continue to be a big problem in American healthcare and this emerging NASDAQ company has a solution for a common one. Wall Street may soon have its eye on this growing player in the eye disease market, as it is developing first-in-class pharmaceutical therapies to treat inflammatory eye diseases. The company’s immediate goal is the development of a first-in-class drug that combines both anti-inflammatory and ocular pain-reducing activity to treat dry eye disease (DED). Worldwide, 360 million patients suffer from DED. In the United States, 20 million patients suffer from this condition, with DED remaining a major unmet medical need. This company’s game-changing drug candidate is being developed to treat DED, a condition that is a significant unmet need in a multi-billion-dollar market. Now may be a critical time to have the company on your radar as not long ago, the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) to initiate a Phase 2, first-in-human, clinical study of their drug candidate for the treatment of DED! Should the company be successful with the results from the clinical trial in Q4 2023, the company could be in a strong negotiating position to clinch a business development partnership or trade sale to Big Pharma. Q4 is around the corner! See why positive developments on the company’s drug candidate could trigger some exponential moves northward! Thank you for subscribing to DividendStocks.com's daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.   This message is a paid advertisement sent on behalf of Smallcaps Daily, a third-party advertiser of DividendStocks.com and MarketBeat.     This message is a paid advertisement for Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO) from $7,000 and Smallcap Daily. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to [XX_AMOUNT_XX]. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Interactive Offers or Smallcap Daily. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO) on Smallcap Daily' website for additional information about the relationship between Smallcap Daily and Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO).     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.   If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 326 E 8th St #105, Sioux Falls, SD 57103. United States.   Today's Bonus Content: This is the #1 Stock to Buy for the AI Tidal Wave